Antipsychotic "Black Box" Warning Will Caution Against Off-Label Use In Dementia

FDA is requesting class labeling describing clinical trial results that show a higher rate of mortality in patients treated with atypical antipsychotics for dementia-related behavioral disorders compared to placebo. FDA's public health advisory and physician alert affect seven products.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet